The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma.
As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of 12 800 pound silver-17 600 pound silver, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.
Beard
S M
SM
ScHARR, University of Sheffield, UK.
Lorigan
P C
PC
Sampson
F C
FC
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D018572:Disease-Free Survival; D017850:Economics, Pharmaceutical; D006689:Hodgkin Disease / Q000191:economics* / Q000401:mortality / Q000628:therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000191:economics* / Q000401:mortality / Q000628:therapy; D012008:Recurrence; D016879:Salvage Therapy / Q000191:economics*; D012680:Sensitivity and Specificity; D013997:Time Factors
D000970:Antineoplastic Agents